Lucid DiagnosticsLUCD
LUCD
About: Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Employees: 70
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
402% more capital invested
Capital invested by funds: $2.8M [Q4 2024] → $14.1M (+$11.3M) [Q1 2025]
375% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 4
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
47% more funds holding
Funds holding: 32 [Q4 2024] → 47 (+15) [Q1 2025]
5.21% more ownership
Funds ownership: 5.58% [Q4 2024] → 10.79% (+5.21%) [Q1 2025]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$2
98%
upside
Avg. target
$4.25
321%
upside
High target
$7.75
667%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Needham Mike Matson | 197%upside $3 | Buy Reiterated | 16 Jul 2025 |
Ascendiant Capital Edward Woo | 667%upside $7.75 | Buy Maintained | 6 Jun 2025 |
Cantor Fitzgerald Ross Osborn | 98%upside $2 | Overweight Reiterated | 15 May 2025 |
Financial journalist opinion
Based on 3 articles about LUCD published over the past 30 days
Neutral
PRNewsWire
16 hours ago
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, August 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D.
Neutral
PRNewsWire
16 hours ago
PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
NEW YORK , July 30, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it had received written notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") that the Company was eligible for a 180-day extension to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule"). The Company now has until January 19, 2026 to meet the requirement.
Neutral
PRNewsWire
2 weeks ago
MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test
Virtual public CAC meeting to be held September 4, 2025, at 2:00 p.m. ET NEW YORK , July 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that on Thursday, September 4, 2025, from 2:00 to 4:00 p.m.
Neutral
PRNewsWire
1 month ago
Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test
Lucid to partner with Hoag in its mission to eradicate esophageal cancer by expanding access to EsoGuard precancer testing across its extensive healthcare delivery network NEW YORK , June 18, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Hoag, a nationally-recognized regional healthcare delivery network, has launched a comprehensive, integrated esophageal precancer testing program using Lucid Diagnostics' EsoGuard® Esophageal DNA Test. Lucid will partner with Hoag to offer EsoGuard testing across its digestive health, primary care, and concierge medicine programs.
Neutral
PRNewsWire
2 months ago
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
NEW YORK , May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Lucid is joining these important market indices, which serve as leading benchmarks for institutional investors and as the basis for numerous index-linked financial products," said Dennis McGrath , Lucid's Chief Financial Officer.
Neutral
PRNewsWire
2 months ago
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results
Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Veris Health completed 1Q25 financing, resumed development of implantable physiological monitor, and will soon launch first commercial partnership with major cancer center PAVmed seeking to leverage infrastructure and expand into biopharma sector; actively evaluating clinical and late preclinical stage assets Conference call and webcast to be held today, May 15 th, at 8:30 AM EDT NEW YORK , May 15, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and reported financial results for the quarter ended March 31, 2025. Conference Call and Webcast The webcast will take place on Thursday, May 15, 2025, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.
Neutral
Seeking Alpha
2 months ago
Lucid Diagnostics Inc. (LUCD) Q1 2025 Business Update Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q1 2025 Business Update Conference Call May 14, 2025 8:30 AM ET Company Participants Matt Riley – Senior Director-Investor Relations Lishan Aklog – Chairman and Chief Executive Officer Dennis McGrath – Chief Financial Officer Conference Call Participants Mark Massaro – BTIG Kyle Mikson – Canaccord Genuity Mike Matson – Needham & Company Jeremy Pearlman – Maxim Group Ross Osborn – Cantor Fitzgerald Ed Woo – Ascendiant Capital Operator Good morning and welcome to the Lucid Diagnostics First Quarter 2025 Business Update Conference Call. Please note, this event is being recorded.
Negative
Zacks Investment Research
2 months ago
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue Estimates
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.21 per share a year ago.
Neutral
PRNewsWire
2 months ago
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results
Processed 3,034 EsoGuard® tests and recognized revenue of $0.8 million in 1Q25 Secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Conference call and webcast to be held today, May 14 th, at 8:30 AM EDT NEW YORK , May 14, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the three months ended March 31, 2025. Conference Call and Webcast The webcast will take place on Wednesday, May 14, 2025, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com.
Negative
Zacks Investment Research
2 months ago
Will Lucid Diagnostics Inc. (LUCD) Report Negative Earnings Next Week? What You Should Know
Lucid Diagnostics (LUCD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charts implemented using Lightweight Charts™